News
The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...
The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional ...
Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.
5don MSN
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Our current Medical Establishment doesn't seem to grasp that they are no longer just Fox News and Twitter celebrities who can ...
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
DEFINITION OF ELDERLY IS THEY’RE SAYING 65 AND OLDER. The U.S. Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results